

# European Respiratory Society Annual Congress 2012

**Abstract Number:** 3486

**Publication Number:** 3118

**Abstract Group:** 5.3. Allergy and Immunology

**Keyword 1:** COPD - exacerbations **Keyword 2:** Immunology **Keyword 3:** Infections

**Title:** The IL-2-dependent Th1 response to bacterial infections is suppressed in COPD

Dr. Juergen 19005 Knobloch juergen.knobloch@bergmannsheil.de <sup>1</sup>, Ms. Sarah 19006 Chikosi sarah@chikosi@bergmannsheil.de MD <sup>1</sup>, Mr. David 19007 Jungck david.jungck@bergmannsheil.de MD <sup>1</sup> and Dr. Andrea 19008 Koch andrea.koch@bergmannsheil.de MD <sup>1</sup>. <sup>1</sup> Medical Clinic III for Pneumology, Allergology, Sleep- and Respiratormedicine, University Hospital Bochum-Bergmannsheil, Bochum, NRW, Germany, D-44789 .

**Body:** Susceptibility to bacterial infections is enhanced in COPD, which promotes exacerbations. IL-2 triggers proliferation of Th1 cells important for infection defence. We elucidated modulation of IL-2 release from Th1 cells by LPS and in COPD. Peripheral blood CD4<sup>+</sup> cells of n=10 age-/gender-matched never-smokers (NS), smokers without (S) and with COPD were ex vivo activated towards Th1 by  $\alpha$ CD3/ $\alpha$ CD28 antibodies and IL-12. IL-2 release (ELISA) and cell count/death was analyzed after 24-96h of cultivation. Activation towards Th1 increased IL-2 release and cell count. IL-2 release was increased in COPD and negatively correlated to FEV<sub>1</sub> [% pred.]. Nonetypeable H. influenzae extract suppressed IL-2 release from Th1 cells of NS, which was abolished by Polymyxin B or CLI095 (LPS/TLR4 inhibitors). LPS reduced IL-2 release and cell count of Th1 cells, these effects were enhanced in COPD. LPS effect on IL-2 negatively correlated with FEV<sub>1</sub> [% pred.] and was abolished by CLI095. In the presence of LPS, blocking MyD88/IRAK was more efficient in restoring IL-2 release in NS vs. COPD, whereas blocking TRIF/IKK $\epsilon$  was more efficient in COPD, and moxifloxacin (MXF) increased IL-2 release and cell count of Th1 cells. MXF effect on IL-2 was enhanced in COPD and correlated to the IL-2-inducing effect of p38MAPK inhibitor SB203580. All effects were p<0.05. LPS and MXF did not induce Th1 cell death. Th1 response to bacterial infections is impaired in COPD due to a shift from MyD88/IRAK to TRIF/IKK $\epsilon$  signalling, which enhances suppression of IL-2 and Th1 growth by LPS. MXF might reinforce IL-2 expression and Th1 growth by blocking p38MAPK signalling. Targeting TLR4 signalling combined with MXF might reduce exacerbation rates.